Navigation Links
Novel therapeutic approaches may improve patient outcomes in several platelet disorders
Date:12/6/2008

(SAN FRANCISCO, December 6, 2008) Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, will be presented in a press conference on Saturday, December 6, at 8:00 a.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. The studies featured in the press conference will report on a new combination therapy for previously untreated idiopathic thrombocytopenic purpura (ITP), an investigational oral treatment for chronic ITP, a low-dose platelet transfusion strategy for patients with hypoproliferative thrombocytopenia, and a new therapeutic platelet transfusion approach following high-dose chemotherapy and autologous stem cell transplantation.

"We have some very exciting data on novel therapeutic approaches to minimize bleeding episodes in patients with platelet disorders," said press conference moderator Kenneth Kaushansky, MD, 2008 President of the American Society of Hematology and Helen M. Ranney Professor and Chair of the Department of Medicine at the University of California, San Diego School of Medicine. "The results of these studies will likely transform the way hematologists treat and manage these conditions, ultimately resulting in improvements in overall patient outcomes such as reducing bruising and unnecessary bleeding that can result if left untreated."

Types of thrombocytopenia, a blood disorder with 50 to 150 new cases per 1 million people each year, are typically classified by one of three causes: low production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream, or increased breakdown of platelets in the spleen or liver, which can be induced by certain anemias, cancers, infections, or medications. Symptoms can include bruising, nose bleeds, bleeding in the mouth, and rash-like spots on the
'/>"/>

Contact: Laura Stark
lstark@hematology.org
415-978-3505
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...nt to 113 chest X-rays, study finds , , ... of patients who have abdominal/pelvic CT scans re...pose them to extra radiation, U.S. researchers say...eries were performed on 500 patients aged 9 months...ears of age. The researchers concluded that 35.3 p...
(Date:11/30/2009)...unique online and mobile tool empowers patients to...isions ,, ARLINGTON, Va., Nov. 30 /PRNewswir...#1 HIV/AIDS resource online, today launched My Hea...V/AIDS-infected patients the ability to save, trac...d with sponsorship from Merck, is available at ww...
(Date:11/30/2009)...Nov. 30 Tyco Internation...10 annual general meeting of shareholders will be ...tral European time at the Park Hyatt Zurich Hotel,...egistered shareholders as of January 11, 2010 (the...al general meeting. Additionally, individuals who...
(Date:11/30/2009)... and extensive discussion in the scientific commun...ealth Care (IQWiG) presents its methods for evalua...stitute can now apply these methods when working o... Committee (G-BA). The method developed by IQWiG i...KV-Spitzenverband [National Association of Health ...
(Date:11/30/2009)...Newswire/ -- Reportlinker.com announces that a new...gue: ,, Key Players and Innovative Start-Ups i...ts, pharma, food and drinks ,, http://www.rep...Start-Ups-in-Nutraceuticals-Emerging-strategies-in...traceuticals are bioactive compounds with properti...
Breaking Medicine News(10 mins):Health News:CT Scan Patients May Get Unnecessary Imaging 2Health News:TheBody.com Launches My Health Tracker, Enabling HIV-Positive Patients to Track Lab Results, Medications and Supplements 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 3Health News:IQWiG presents a method for evaluating the relation between cost and benefit 4Health News:IQWiG presents a method for evaluating the relation between cost and benefit 5Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 2Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 3Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 4Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 5Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 6
...ver for those who prefer relaxing with a good cup ...ed by researchers from Charite Hospital Universita...European Heart Journal, has come out with a study ...hich protect the heart and have anti-cancer effect...
... in adolescents and young adults was associated wi...heart//, researchers report in Circulation: Journa...udy of American Indians, average age 26.5, those w... ventricular wall thickness, higher left ventricul...
...er week are at greater risk of developing osteoart...ccording to research conducted by the University o...is characterised by joint pain, which can be relie...s arose in the long-distance joggers' knees, said ...
...age healing through mantras! Sanskrit scholars of ...rsity// have initiated a research project, said to...es through Vedic chants. A state-of-the-art a...icipating in the research. The lab would inv...
... is a boon for the kith and kin of those people wh...vaccine is currently available in 33 countries all...rp & Dohme. This vaccine was formed by Professor I...g contender for Nobel Prize. In the middle E...
...California heaved a sigh of relief when the health...tween the meningitis// and the encephalitis cases ... have clearly indicated that the bacteria, which c...erial infection. An elementary school studen...
Other Medicine News:Health News:Hypertension, Prehypertension in Youngsters Linked With Heart Enlargement 2Health News:Hypertension, Prehypertension in Youngsters Linked With Heart Enlargement 3
(Date:11/30/2009)...L, Wash., Nov. 30 SCOLR ...at on November 25, 2009, the NYSE Amex LLC (the "E...d the Company,s plan to comply with its previously...)(iv) of the Exchange Company Guide. Specifically...stained losses which were so substantial in relati...
(Date:11/30/2009)...STON, S.C., Nov. 30 The Eleventh A...", will be held at the Charleston Place Hotel in t...r 3-4, 2009. Dr. Cheryl Liljestrand, Dr. Harry Gu...s with Stipkala LLC, will attend. SEBIO 2009 prom...nvestors, scientists, entrepreneurs, and service p...
(Date:11/30/2009)...W YORK, Nov. 30 Reportlinker.com a...lable in its catalogue: ,, Cardiac Defibrillat..., http://www.reportlinker.com/p0164315/Cardiac-De...ort.html ,, Cardiovascular disease (CVD) is o...den cardiac arrest survivors are prone to arrhythm...
Breaking Medicine Technology:SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 2Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 3Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 4Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 5Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 6Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 7Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 8International Isotopes Inc Announces Second Quarter and Six Months 2009 Financial Results 54312 1International Isotopes Inc Announces Second Quarter and Six Months 2009 Financial Results 54312 2International Isotopes Inc Announces Second Quarter and Six Months 2009 Financial Results 54312 3International Isotopes Inc Announces Second Quarter and Six Months 2009 Financial Results 54312 4International Isotopes Inc Announces Second Quarter and Six Months 2009 Financial Results 54312 5International Isotopes Inc Announces Second Quarter and Six Months 2009 Financial Results 54312 6International Isotopes Inc Announces Second Quarter and Six Months 2009 Financial Results 54312 7Sage Software Healthcare Inc Celebrates National Health Center Week 54311 1Sage Software Healthcare Inc Celebrates National Health Center Week 54311 2Cystic Fibrosis Foundation Receives Second 4 Star Rating from Charity Navigator for Exceptional Fiscal Management 54308 1Cystic Fibrosis Foundation Receives Second 4 Star Rating from Charity Navigator for Exceptional Fiscal Management 54308 2
...S WIRE)--Apr 14, 2007 - In a late-breaker,presenta...sociation,for the Study of the Liver (EASL), resea... analysis of the PROVE 1 clinical trial,which is ... with,the investigational hepatitis C protease inh...h pegylated interferon (peg-IFN) and,ribavirin (RB...
...RNewswire-FirstCall/ -- ACCESS,PHARMACEUTICALS, IN...mechanism of ProLindac,s anticancer activity will ... Cancer Research (AACR) 2007,annual meeting in Los... two poster presentations describe preclinical stu...inent institutes in France. , "We are delighted to...
Other Medicine Technology:Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8Access Pharmaceuticals Announces Poster Presentations on ProLindac,at the American Association for Cancer Research 2007 Annual Meeting 2Access Pharmaceuticals Announces Poster Presentations on ProLindac,at the American Association for Cancer Research 2007 Annual Meeting 3Access Pharmaceuticals Announces Poster Presentations on ProLindac,at the American Association for Cancer Research 2007 Annual Meeting 4
Silicone Wedge (137 Style)
Silicone Tire (281 Style)
Silicone Strip (225 Style)
Silicone Boat (60 Style)
Medicine Products: